Obesity – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：381頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Obesity – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Obesity - Pipeline Review, H2 2012', provides an overview of the Obesity therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. 'Obesity - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Obesity.
- A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Obesity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Obesity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Obesity - Pipeline Review, H2 2012', provides an overview of the Obesity therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. 'Obesity - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Obesity.
- A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Obesity pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Obesity.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Obesity therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Obesity Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Obesity 15
Obesity Therapeutics under Development by Companies 17
Obesity Therapeutics under Investigation by Universities/Institutes 24
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Obesity Therapeutics – Products under Development by Companies 31
Obesity Therapeutics – Products under Investigation by Universities/Institutes 39
Companies Involved in Obesity Therapeutics Development 41
Bristol-Myers Squibb Company 41
Boehringer Ingelheim GmbH 42
F. Hoffmann-La Roche Ltd. 43
Shionogi & Co., Ltd. 44
AstraZeneca PLC 45
Eli Lilly and Company 46
NeuroSearch A/S 73
Orchid Chemicals & Pharmaceuticals Ltd 74
Corcept Therapeutics Incorporated 75
Arena Pharmaceuticals, Inc. 76
Emisphere Technologies, Inc. 77
Unigene Laboratories, Inc. 78
Theratechnologies Inc. 79
LG Life Sciences, Ltd 80
Transition Therapeutics Inc. 81
Suven Life Sciences Ltd. 82
Galapagos NV 83
Phynova Group Ltd 84
Proximagen Neuroscience plc. 85
Orexigen Therapeutics, Inc. 86
Advinus Therapeutics Pvt. Ltd. 87
Sirtris Pharmaceuticals, Inc. 88
Jenrin Discovery, Inc. 89
ObeTherapy Biotechnology 90
7TM Pharma A/S 91
Metabolex, Inc 92
Helsinn Healthcare S.A. 93
Xenon Pharmaceuticals Inc. 94
Spherix Incorporated 95
AngioChem Inc. 96
Global Health Ventures Inc. 97
Zafgen Inc. 98
Ambrx, Inc. 99
Lithera, Inc. 118
Sirona Biochem Corp 119
Reviva Pharmaceuticals Inc. 120
PharmaIN Corporation 121
Rhythm Pharmaceuticals 122
Obesity – Therapeutics Assessment 123
Assessment by Monotherapy Products 123
Assessment by Combination Products 124
Assessment by Route of Administration 125
Assessment by Molecule Type 127
Drug Profiles 130
MEM 68626 - Drug Profile 130
Cametor - Drug Profile 131
Qsymia - Drug Profile 133
Belviq - Drug Profile 135
5HT2C Agonist - Drug Profile 138
11ßHSD Enzyme Inhibitor - Drug Profile 139
AEZS-123 - Drug Profile 140
CSC 500 Series - Drug Profile 141
TM38837 - Drug Profile 142
TM30339 - Drug Profile 144
TGFTX2 Program - Drug Profile 145
GFT505 - Drug Profile 146
Nuclear Receptor Program - Drug Profile 148
Leptin - Drug Profile 175
NOX-B11 - Drug Profile 176
SGLT-2 Inhibitor - Drug Profile 177
OAP-189 - Drug Profile 178
JD-2000 Series - Drug Profile 180
Velneperit - Drug Profile 186
Victoza - Drug Profile 187
ALB-127158(a) - Drug Profile 189
FAS89B - Drug Profile 191
FAS 267 - Drug Profile 192
ZYD1 - Drug Profile 193
SRT1720 - Drug Profile 194
TA-7284 - Drug Profile 195
Xenical - Drug Profile 197
HPP404 - Drug Profile 198
PRX00933 - Drug Profile 199
KGT-1681 - Drug Profile 200
LIPO-102 - Drug Profile 202
Leptin - Drug Profile 204
Botox - Drug Profile 205
Exenatide - Drug Profile 207
A-100 - Drug Profile 208
Betahistine - Drug Profile 209
Byetta - Drug Profile 211
Metformin - Drug Profile 212
BGP-15 - Drug Profile 213
Diazoxide - Drug Profile 214
Drug For Obesity - Drug Profile 215
S-234462 - Drug Profile 216
2-Hydroxyoleic Acid - Drug Profile 217
Betahistine - Drug Profile 218
Metformin - Drug Profile 219
PP 1420 - Drug Profile 221
ZYOG1 - Drug Profile 222
RM-493 - Drug Profile 223
Novorapid + Amaryl - Drug Profile 224
ZGN-201 - Drug Profile 226
VRS-859 + AMX-808 - Drug Profile 227
ANG2004 - Drug Profile 229
CKD-732 - Drug Profile 230
Recombinant Human Growth Hormone - Drug Profile 232
GRC 9332 - Drug Profile 233
Drug For Type 2 Diabetes And Obesity - Drug Profile 234
Naltrexone + Nicotine - Drug Profile 236
Leptin - Drug Profile 237
GW42004 + GW42003 - Drug Profile 238
ND0801 - Drug Profile 240
Botulinum Toxin Type A - Drug Profile 241
BMS-830216 - Drug Profile 242
Diazoxide - Drug Profile 243
Sertraline + Telenzepine - Drug Profile 244
Exenatide - Drug Profile 246
5-HT2C Agonists For Obesity - Drug Profile 247
UGP-281 - Drug Profile 248
OB3 Peptide - Drug Profile 249
Fatostatin - Drug Profile 250
ZAG - Drug Profile 251
DNA-PK - Drug Profile 252
IMPDH Inhibitors For Obesity - Drug Profile 253
Leptin Mimetic - Drug Profile 254
Metformin + Diazoxide - Drug Profile 255
OBE 2001 - Drug Profile 256
Femara - Drug Profile 257
Lipid Absorption Inhibitor - Drug Profile 258
MAR-709 - Drug Profile 259
TT401 - Drug Profile 260
TT402 - Drug Profile 261
Flutamide + Metformin - Drug Profile 262
ISIS-FGFR4 - Drug Profile 263
MOD-1001 - Drug Profile 264
MOD-1002 - Drug Profile 265
Diacerein - Drug Profile 266
Metformin - Drug Profile 267
RP-1000 - Drug Profile 268
GPR85 Antagonist - Drug Profile 269
CPT1 Inhibitors - Drug Profile 270
Ghrelin Antagonists - Drug Profile 271
ST2425 - Drug Profile 272
ZGN-440 - Drug Profile 273
CD14 Project - Drug Profile 274
PGC GLP-1 - Drug Profile 275
PD4048 - Drug Profile 276
PD4074 - Drug Profile 277
Anti-Obesity Drug - Drug Profile 278
Drug For Obesity And Diabetes - Drug Profile 279
PD2024 - Drug Profile 280
PD4074 + PD4048 - Drug Profile 281
TBK1/ IKKe Inhibitors - Drug Profile 282
GPR39 Antagonist - Drug Profile 283
T-Slim - Drug Profile 284
Adipotide - Drug Profile 291
Y242 - Drug Profile 293
Drug for Obesity - Drug Profile 294
Target 2 For Type 2 Diabetes/Obesity - Drug Profile 295
Target 4 For Type 2 Diabetes/Obesity - Drug Profile 296
GSK2374697 - Drug Profile 297
ZYGL241 - Drug Profile 298
KD-026 - Drug Profile 299
OBE1999 - Drug Profile 300
OBE2000 - Drug Profile 301
OBE2002 - Drug Profile 302
EDP 21 - Drug Profile 303
PTP1B inhibitors - Drug Profile 304
Drug Targeting GPR21 - Drug Profile 305
JH-17 - Drug Profile 306
JH-18 - Drug Profile 307
Enterocyte-Directed DGAT-1 Inhibitor Program - Drug Profile 308
Obesity Therapeutics – Drug Profile Updates 309
Obesity Therapeutics – Discontinued Products 345
Obesity Therapeutics - Dormant Products 351
Obesity – Product Development Milestones 362
Featured News & Press Releases 362
Appendix 370
Methodology 370
Coverage 370
Secondary Research 370
Primary Research 370
Expert Panel Validation 370
Contact Us 371
Disclaimer 371
List of Tables
Number of Products Under Development for Obesity, H2 2012 25
Products under Development for Obesity – Comparative Analysis, H2 2012 26
Number of Products under Development by Companies, H2 2012 28
Number of Products under Development by Companies, H2 2012 (Contd..1) 29
Number of Products under Development by Companies, H2 2012 (Contd..2) 30
Number of Products under Development by Companies, H2 2012 (Contd..3) 31
Number of Products under Development by Companies, H2 2012 (Contd..4) 32
Number of Products under Development by Companies, H2 2012 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 36
Comparative Analysis by Late Stage Development, H2 2012 37
Comparative Analysis by Mid Clinical Stage Development, H2 2012 38
Comparative Analysis by Early Clinical Stage Development, H2 2012 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 40
Products under Development by Companies, H2 2012 41
Products under Development by Companies, H2 2012 (Contd..1) 42
Products under Development by Companies, H2 2012 (Contd..2) 43
Products under Development by Companies, H2 2012 (Contd..3) 44
Products under Development by Companies, H2 2012 (Contd..4) 45
Products under Development by Companies, H2 2012 (Contd..5) 46
Products under Development by Companies, H2 2012 (Contd..6) 47
Products under Development by Companies, H2 2012 (Contd..7) 48
Products under Investigation by Universities/Institutes, H2 2012 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 50
Bristol-Myers Squibb Company, H2 2012 51
Boehringer Ingelheim GmbH, H2 2012 52
F. Hoffmann-La Roche Ltd., H2 2012 53
Shionogi & Co., Ltd., H2 2012 54
AstraZeneca PLC, H2 2012 55
Eli Lilly and Company, H2 2012 56
Athersys, Inc., H2 2012 57
GlaxoSmithKline plc, H2 2012 58
Isis Pharmaceuticals, Inc., H2 2012 59
FASgen, Inc., H2 2012 60
Novo Nordisk A/S, H2 2012 61
Albany Molecular Research, Inc., H2 2012 62
Plexxikon Inc., H2 2012 63
BioLineRx, Ltd., H2 2012 64
Ipsen S.A., H2 2012 65
Chong Kun Dang Pharmaceutical, H2 2012 66
Glenmark Pharmaceuticals Ltd., H2 2012 67
Kissei Pharmaceutical Co., Ltd., H2 2012 68
Mitsubishi Tanabe Pharma Corporation, H2 2012 69
Norgine Limited, H2 2012 70
Pfizer Inc., H2 2012 71
Sigma-Tau S.p.A., H2 2012 72
VIVUS, Inc., H2 2012 73
Zydus Cadila Healthcare Limited, H2 2012 74
GW Pharmaceuticals plc, H2 2012 75
AEterna Zentaris Inc., H2 2012 76
Genfit, H2 2012 77
Arrowhead Research Corporation, H2 2012 78
Ligand Pharmaceuticals Incorporated, H2 2012 79
Lupin Limited, H2 2012 80
Calzada Limited, H2 2012 81
PROLOR Biotech, Inc., H2 2012 82
NeuroSearch A/S, H2 2012 83
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012 84
Corcept Therapeutics Incorporated, H2 2012 85
Arena Pharmaceuticals, Inc., H2 2012 86
Emisphere Technologies, Inc., H2 2012 87
Unigene Laboratories, Inc., H2 2012 88
Theratechnologies Inc., H2 2012 89
LG Life Sciences, Ltd, H2 2012 90
Transition Therapeutics Inc., H2 2012 91
Suven Life Sciences Ltd., H2 2012 92
Galapagos NV, H2 2012 93
Phynova Group Ltd, H2 2012 94
Proximagen Neuroscience plc., H2 2012 95
Orexigen Therapeutics, Inc., H2 2012 96
Advinus Therapeutics Pvt. Ltd., H2 2012 97
Sirtris Pharmaceuticals, Inc., H2 2012 98
Jenrin Discovery, Inc., H2 2012 99
ObeTherapy Biotechnology, H2 2012 100
7TM Pharma A/S, H2 2012 101
Metabolex, Inc, H2 2012 102
Helsinn Healthcare S.A., H2 2012 103
Xenon Pharmaceuticals Inc., H2 2012 104
Spherix Incorporated, H2 2012 105
AngioChem Inc., H2 2012 106
Global Health Ventures Inc., H2 2012 107
Zafgen Inc., H2 2012 108
Ambrx, Inc., H2 2012 109
Tranzyme Pharma, Inc., H2 2012 110
Braasch Biotech LLC, H2 2012 111
Zealand Pharma A/S, H2 2012 112
Indus Biotech Private Limited, H2 2012 113
Intarcia Therapeutics, Inc., H2 2012 114
Theracos, Inc., H2 2012 115
Thrasos, Inc., H2 2012 116
Versartis, Inc., H2 2012 117
Avaxia Biologics, Inc., H2 2012 118
Omeros Corporation, H2 2012 119
Aegis Therapeutics, LLC, H2 2012 120
BRIDGE BIORESEARCH PLC, H2 2012 121
N-Gene Research Laboratories, Inc., H2 2012 122
PepTcell Limited, H2 2012 123
Galenea Corp., H2 2012 124
Verva Pharmaceuticals Limited, H2 2012 125
Adamed Sp. z o.o., H2 2012 126
Domainex Ltd., H2 2012 127
Lithera, Inc., H2 2012 128
Sirona Biochem Corp, H2 2012 129
Reviva Pharmaceuticals Inc., H2 2012 130
PharmaIN Corporation, H2 2012 131
Rhythm Pharmaceuticals, H2 2012 132
Assessment by Monotherapy Products, H2 2012 133
Assessment by Combination Products, H2 2012 134
Assessment by Stage and Route of Administration, H2 2012 136
Assessment by Stage and Molecule Type, H2 2012 139
Obesity Therapeutics – Drug Profile Updates 319
Obesity Therapeutics – Discontinued Products 355
Obesity Therapeutics – Discontinued Products (Contd..1) 356
Obesity Therapeutics – Discontinued Products (Contd..2) 357
Obesity Therapeutics – Discontinued Products (Contd..3) 358
Obesity Therapeutics – Discontinued Products (Contd..4) 359
Obesity Therapeutics – Discontinued Products (Contd..5) 360
Obesity Therapeutics – Dormant Products 361
Obesity Therapeutics – Dormant Products (Contd..1) 362
Obesity Therapeutics – Dormant Products (Contd..2) 363
Obesity Therapeutics – Dormant Products (Contd..3) 364
Obesity Therapeutics – Dormant Products (Contd..4) 365
Obesity Therapeutics – Dormant Products (Contd..5) 366
Obesity Therapeutics – Dormant Products (Contd..6) 367
Obesity Therapeutics – Dormant Products (Contd..7) 368
Obesity Therapeutics – Dormant Products (Contd..8) 369
Obesity Therapeutics – Dormant Products (Contd..9) 370
Obesity Therapeutics – Dormant Products (Contd..10) 371
List of Figures
Number of Products under Development for Obesity, H2 2012 25
Products under Development for Obesity – Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 34
Late Stage Products, H2 2012 37
Mid Clinical Stage Products, H2 2012 38
Early Clinical Stage Products, H2 2012 39
Discovery and Pre-Clinical Stage Products, H2 2012 40
Assessment by Monotherapy Products, H2 2012 133
Assessment by Combination Products, H2 2012 134
Assessment by Route of Administration, H2 2012 135
Assessment by Stage and Route of Administration, H2 2012 136
Assessment by Molecule Type, H2 2012 137
Assessment by Stage and Molecule Type, H2 2012 138
Table of Contents 2
List of Tables 9
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Obesity Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Obesity 15
Obesity Therapeutics under Development by Companies 17
Obesity Therapeutics under Investigation by Universities/Institutes 24
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Obesity Therapeutics – Products under Development by Companies 31
Obesity Therapeutics – Products under Investigation by Universities/Institutes 39
Companies Involved in Obesity Therapeutics Development 41
Bristol-Myers Squibb Company 41
Boehringer Ingelheim GmbH 42
F. Hoffmann-La Roche Ltd. 43
Shionogi & Co., Ltd. 44
AstraZeneca PLC 45
Eli Lilly and Company 46
NeuroSearch A/S 73
Orchid Chemicals & Pharmaceuticals Ltd 74
Corcept Therapeutics Incorporated 75
Arena Pharmaceuticals, Inc. 76
Emisphere Technologies, Inc. 77
Unigene Laboratories, Inc. 78
Theratechnologies Inc. 79
LG Life Sciences, Ltd 80
Transition Therapeutics Inc. 81
Suven Life Sciences Ltd. 82
Galapagos NV 83
Phynova Group Ltd 84
Proximagen Neuroscience plc. 85
Orexigen Therapeutics, Inc. 86
Advinus Therapeutics Pvt. Ltd. 87
Sirtris Pharmaceuticals, Inc. 88
Jenrin Discovery, Inc. 89
ObeTherapy Biotechnology 90
7TM Pharma A/S 91
Metabolex, Inc 92
Helsinn Healthcare S.A. 93
Xenon Pharmaceuticals Inc. 94
Spherix Incorporated 95
AngioChem Inc. 96
Global Health Ventures Inc. 97
Zafgen Inc. 98
Ambrx, Inc. 99
Lithera, Inc. 118
Sirona Biochem Corp 119
Reviva Pharmaceuticals Inc. 120
PharmaIN Corporation 121
Rhythm Pharmaceuticals 122
Obesity – Therapeutics Assessment 123
Assessment by Monotherapy Products 123
Assessment by Combination Products 124
Assessment by Route of Administration 125
Assessment by Molecule Type 127
Drug Profiles 130
MEM 68626 - Drug Profile 130
Cametor - Drug Profile 131
Qsymia - Drug Profile 133
Belviq - Drug Profile 135
5HT2C Agonist - Drug Profile 138
11ßHSD Enzyme Inhibitor - Drug Profile 139
AEZS-123 - Drug Profile 140
CSC 500 Series - Drug Profile 141
TM38837 - Drug Profile 142
TM30339 - Drug Profile 144
TGFTX2 Program - Drug Profile 145
GFT505 - Drug Profile 146
Nuclear Receptor Program - Drug Profile 148
Leptin - Drug Profile 175
NOX-B11 - Drug Profile 176
SGLT-2 Inhibitor - Drug Profile 177
OAP-189 - Drug Profile 178
JD-2000 Series - Drug Profile 180
Velneperit - Drug Profile 186
Victoza - Drug Profile 187
ALB-127158(a) - Drug Profile 189
FAS89B - Drug Profile 191
FAS 267 - Drug Profile 192
ZYD1 - Drug Profile 193
SRT1720 - Drug Profile 194
TA-7284 - Drug Profile 195
Xenical - Drug Profile 197
HPP404 - Drug Profile 198
PRX00933 - Drug Profile 199
KGT-1681 - Drug Profile 200
LIPO-102 - Drug Profile 202
Leptin - Drug Profile 204
Botox - Drug Profile 205
Exenatide - Drug Profile 207
A-100 - Drug Profile 208
Betahistine - Drug Profile 209
Byetta - Drug Profile 211
Metformin - Drug Profile 212
BGP-15 - Drug Profile 213
Diazoxide - Drug Profile 214
Drug For Obesity - Drug Profile 215
S-234462 - Drug Profile 216
2-Hydroxyoleic Acid - Drug Profile 217
Betahistine - Drug Profile 218
Metformin - Drug Profile 219
PP 1420 - Drug Profile 221
ZYOG1 - Drug Profile 222
RM-493 - Drug Profile 223
Novorapid + Amaryl - Drug Profile 224
ZGN-201 - Drug Profile 226
VRS-859 + AMX-808 - Drug Profile 227
ANG2004 - Drug Profile 229
CKD-732 - Drug Profile 230
Recombinant Human Growth Hormone - Drug Profile 232
GRC 9332 - Drug Profile 233
Drug For Type 2 Diabetes And Obesity - Drug Profile 234
Naltrexone + Nicotine - Drug Profile 236
Leptin - Drug Profile 237
GW42004 + GW42003 - Drug Profile 238
ND0801 - Drug Profile 240
Botulinum Toxin Type A - Drug Profile 241
BMS-830216 - Drug Profile 242
Diazoxide - Drug Profile 243
Sertraline + Telenzepine - Drug Profile 244
Exenatide - Drug Profile 246
5-HT2C Agonists For Obesity - Drug Profile 247
UGP-281 - Drug Profile 248
OB3 Peptide - Drug Profile 249
Fatostatin - Drug Profile 250
ZAG - Drug Profile 251
DNA-PK - Drug Profile 252
IMPDH Inhibitors For Obesity - Drug Profile 253
Leptin Mimetic - Drug Profile 254
Metformin + Diazoxide - Drug Profile 255
OBE 2001 - Drug Profile 256
Femara - Drug Profile 257
Lipid Absorption Inhibitor - Drug Profile 258
MAR-709 - Drug Profile 259
TT401 - Drug Profile 260
TT402 - Drug Profile 261
Flutamide + Metformin - Drug Profile 262
ISIS-FGFR4 - Drug Profile 263
MOD-1001 - Drug Profile 264
MOD-1002 - Drug Profile 265
Diacerein - Drug Profile 266
Metformin - Drug Profile 267
RP-1000 - Drug Profile 268
GPR85 Antagonist - Drug Profile 269
CPT1 Inhibitors - Drug Profile 270
Ghrelin Antagonists - Drug Profile 271
ST2425 - Drug Profile 272
ZGN-440 - Drug Profile 273
CD14 Project - Drug Profile 274
PGC GLP-1 - Drug Profile 275
PD4048 - Drug Profile 276
PD4074 - Drug Profile 277
Anti-Obesity Drug - Drug Profile 278
Drug For Obesity And Diabetes - Drug Profile 279
PD2024 - Drug Profile 280
PD4074 + PD4048 - Drug Profile 281
TBK1/ IKKe Inhibitors - Drug Profile 282
GPR39 Antagonist - Drug Profile 283
T-Slim - Drug Profile 284
Adipotide - Drug Profile 291
Y242 - Drug Profile 293
Drug for Obesity - Drug Profile 294
Target 2 For Type 2 Diabetes/Obesity - Drug Profile 295
Target 4 For Type 2 Diabetes/Obesity - Drug Profile 296
GSK2374697 - Drug Profile 297
ZYGL241 - Drug Profile 298
KD-026 - Drug Profile 299
OBE1999 - Drug Profile 300
OBE2000 - Drug Profile 301
OBE2002 - Drug Profile 302
EDP 21 - Drug Profile 303
PTP1B inhibitors - Drug Profile 304
Drug Targeting GPR21 - Drug Profile 305
JH-17 - Drug Profile 306
JH-18 - Drug Profile 307
Enterocyte-Directed DGAT-1 Inhibitor Program - Drug Profile 308
Obesity Therapeutics – Drug Profile Updates 309
Obesity Therapeutics – Discontinued Products 345
Obesity Therapeutics - Dormant Products 351
Obesity – Product Development Milestones 362
Featured News & Press Releases 362
Appendix 370
Methodology 370
Coverage 370
Secondary Research 370
Primary Research 370
Expert Panel Validation 370
Contact Us 371
Disclaimer 371
List of Tables
Number of Products Under Development for Obesity, H2 2012 25
Products under Development for Obesity – Comparative Analysis, H2 2012 26
Number of Products under Development by Companies, H2 2012 28
Number of Products under Development by Companies, H2 2012 (Contd..1) 29
Number of Products under Development by Companies, H2 2012 (Contd..2) 30
Number of Products under Development by Companies, H2 2012 (Contd..3) 31
Number of Products under Development by Companies, H2 2012 (Contd..4) 32
Number of Products under Development by Companies, H2 2012 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 36
Comparative Analysis by Late Stage Development, H2 2012 37
Comparative Analysis by Mid Clinical Stage Development, H2 2012 38
Comparative Analysis by Early Clinical Stage Development, H2 2012 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 40
Products under Development by Companies, H2 2012 41
Products under Development by Companies, H2 2012 (Contd..1) 42
Products under Development by Companies, H2 2012 (Contd..2) 43
Products under Development by Companies, H2 2012 (Contd..3) 44
Products under Development by Companies, H2 2012 (Contd..4) 45
Products under Development by Companies, H2 2012 (Contd..5) 46
Products under Development by Companies, H2 2012 (Contd..6) 47
Products under Development by Companies, H2 2012 (Contd..7) 48
Products under Investigation by Universities/Institutes, H2 2012 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 50
Bristol-Myers Squibb Company, H2 2012 51
Boehringer Ingelheim GmbH, H2 2012 52
F. Hoffmann-La Roche Ltd., H2 2012 53
Shionogi & Co., Ltd., H2 2012 54
AstraZeneca PLC, H2 2012 55
Eli Lilly and Company, H2 2012 56
Athersys, Inc., H2 2012 57
GlaxoSmithKline plc, H2 2012 58
Isis Pharmaceuticals, Inc., H2 2012 59
FASgen, Inc., H2 2012 60
Novo Nordisk A/S, H2 2012 61
Albany Molecular Research, Inc., H2 2012 62
Plexxikon Inc., H2 2012 63
BioLineRx, Ltd., H2 2012 64
Ipsen S.A., H2 2012 65
Chong Kun Dang Pharmaceutical, H2 2012 66
Glenmark Pharmaceuticals Ltd., H2 2012 67
Kissei Pharmaceutical Co., Ltd., H2 2012 68
Mitsubishi Tanabe Pharma Corporation, H2 2012 69
Norgine Limited, H2 2012 70
Pfizer Inc., H2 2012 71
Sigma-Tau S.p.A., H2 2012 72
VIVUS, Inc., H2 2012 73
Zydus Cadila Healthcare Limited, H2 2012 74
GW Pharmaceuticals plc, H2 2012 75
AEterna Zentaris Inc., H2 2012 76
Genfit, H2 2012 77
Arrowhead Research Corporation, H2 2012 78
Ligand Pharmaceuticals Incorporated, H2 2012 79
Lupin Limited, H2 2012 80
Calzada Limited, H2 2012 81
PROLOR Biotech, Inc., H2 2012 82
NeuroSearch A/S, H2 2012 83
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012 84
Corcept Therapeutics Incorporated, H2 2012 85
Arena Pharmaceuticals, Inc., H2 2012 86
Emisphere Technologies, Inc., H2 2012 87
Unigene Laboratories, Inc., H2 2012 88
Theratechnologies Inc., H2 2012 89
LG Life Sciences, Ltd, H2 2012 90
Transition Therapeutics Inc., H2 2012 91
Suven Life Sciences Ltd., H2 2012 92
Galapagos NV, H2 2012 93
Phynova Group Ltd, H2 2012 94
Proximagen Neuroscience plc., H2 2012 95
Orexigen Therapeutics, Inc., H2 2012 96
Advinus Therapeutics Pvt. Ltd., H2 2012 97
Sirtris Pharmaceuticals, Inc., H2 2012 98
Jenrin Discovery, Inc., H2 2012 99
ObeTherapy Biotechnology, H2 2012 100
7TM Pharma A/S, H2 2012 101
Metabolex, Inc, H2 2012 102
Helsinn Healthcare S.A., H2 2012 103
Xenon Pharmaceuticals Inc., H2 2012 104
Spherix Incorporated, H2 2012 105
AngioChem Inc., H2 2012 106
Global Health Ventures Inc., H2 2012 107
Zafgen Inc., H2 2012 108
Ambrx, Inc., H2 2012 109
Tranzyme Pharma, Inc., H2 2012 110
Braasch Biotech LLC, H2 2012 111
Zealand Pharma A/S, H2 2012 112
Indus Biotech Private Limited, H2 2012 113
Intarcia Therapeutics, Inc., H2 2012 114
Theracos, Inc., H2 2012 115
Thrasos, Inc., H2 2012 116
Versartis, Inc., H2 2012 117
Avaxia Biologics, Inc., H2 2012 118
Omeros Corporation, H2 2012 119
Aegis Therapeutics, LLC, H2 2012 120
BRIDGE BIORESEARCH PLC, H2 2012 121
N-Gene Research Laboratories, Inc., H2 2012 122
PepTcell Limited, H2 2012 123
Galenea Corp., H2 2012 124
Verva Pharmaceuticals Limited, H2 2012 125
Adamed Sp. z o.o., H2 2012 126
Domainex Ltd., H2 2012 127
Lithera, Inc., H2 2012 128
Sirona Biochem Corp, H2 2012 129
Reviva Pharmaceuticals Inc., H2 2012 130
PharmaIN Corporation, H2 2012 131
Rhythm Pharmaceuticals, H2 2012 132
Assessment by Monotherapy Products, H2 2012 133
Assessment by Combination Products, H2 2012 134
Assessment by Stage and Route of Administration, H2 2012 136
Assessment by Stage and Molecule Type, H2 2012 139
Obesity Therapeutics – Drug Profile Updates 319
Obesity Therapeutics – Discontinued Products 355
Obesity Therapeutics – Discontinued Products (Contd..1) 356
Obesity Therapeutics – Discontinued Products (Contd..2) 357
Obesity Therapeutics – Discontinued Products (Contd..3) 358
Obesity Therapeutics – Discontinued Products (Contd..4) 359
Obesity Therapeutics – Discontinued Products (Contd..5) 360
Obesity Therapeutics – Dormant Products 361
Obesity Therapeutics – Dormant Products (Contd..1) 362
Obesity Therapeutics – Dormant Products (Contd..2) 363
Obesity Therapeutics – Dormant Products (Contd..3) 364
Obesity Therapeutics – Dormant Products (Contd..4) 365
Obesity Therapeutics – Dormant Products (Contd..5) 366
Obesity Therapeutics – Dormant Products (Contd..6) 367
Obesity Therapeutics – Dormant Products (Contd..7) 368
Obesity Therapeutics – Dormant Products (Contd..8) 369
Obesity Therapeutics – Dormant Products (Contd..9) 370
Obesity Therapeutics – Dormant Products (Contd..10) 371
List of Figures
Number of Products under Development for Obesity, H2 2012 25
Products under Development for Obesity – Comparative Analysis, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 34
Late Stage Products, H2 2012 37
Mid Clinical Stage Products, H2 2012 38
Early Clinical Stage Products, H2 2012 39
Discovery and Pre-Clinical Stage Products, H2 2012 40
Assessment by Monotherapy Products, H2 2012 133
Assessment by Combination Products, H2 2012 134
Assessment by Route of Administration, H2 2012 135
Assessment by Stage and Route of Administration, H2 2012 136
Assessment by Molecule Type, H2 2012 137
Assessment by Stage and Molecule Type, H2 2012 138
